No Data
Ningbo Menovo Pharmaceutical (603538.SH): The subsidiary's Active Pharmaceutical Ingredient for sacubitril/valsartan sodium has passed the CDE technical review.
On March 7, Gelonghui reported that Ningbo Menovo Pharmaceutical (603538.SH) announced that its wholly-owned subsidiary, Xuancheng Ningbo Menovo Pharmaceutical Co., Ltd., received the "Approval Notice for the Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration for the Active Pharmaceutical Ingredient Sacubitril/Valsartan, indicated for the treatment of essential hypertension.
Ningbo Menova Pharmaceutical Co., Ltd. 2024 Annual Results Advance Announcement
Ningbo Menovo Pharmaceutical (603538.SH): The net income for 2024 is expected to increase by 461.04% to 633.67%.
Gelonghui January 27丨Ningbo Menovo Pharmaceutical (603538.SH) announced the preliminary forecast for the annual performance of 2024. According to initial calculations by the finance department, it is expected that the net income attributable to the shareholders of the parent company will be between 65 million yuan and 85 million yuan in 2024, an increase of 53.4144 million yuan to 73.4144 million yuan compared to the same period last year (statutory disclosure data), representing a year-on-year increase of 461.04% to 633.67%. It is expected that the net income attributable to the shareholders of the parent company, after deducting non-recurring gains and losses, will be around 46 million yuan.
Ningbo Menovo Pharmaceutical (603538.SH): Received the Chairman's proposal for the annual dividend for 2024.
On January 23, Gelonghui reported that Ningbo Menovo Pharmaceutical (603538.SH) announced it had received a proposal regarding the 2024 annual dividend from the company's actual controller and Chairman, Mr. Yao Chengzhi. The main content is as follows: "In view of the stable and positive development of the company's production and operation fundamentals in 2024, to actively respond to the 'State Council's Opinions on Strengthening Regulation, Preventing Risks, and Promoting the High-Quality Development of Capital Markets', and to deeply implement regulatory guidelines for listed companies, such as 'Guideline No. 3 for the Regulation of Listed Companies - Cash Dividends for Listed Companies' and the 'Stock Listing Rules of the Shanghai Stock Exchange', to enhance the investment value of listed companies and increase the returns for a broad range of investors."
Ningbo Menovo Pharmaceutical Gets China Approval for Type 2 Diabetes Drug
Ningbo Menovo Pharmaceutical (603538.SH) subsidiary obtained the pharmaceutical registration certificate for Metformin and Vildagliptin Tablets (II).
Ningbo Menovo Pharmaceutical (603538.SH) announced that its wholly-owned subsidiary Ningbo Menovo TianKang Pharmaceutical Co., Ltd. (abbreviation...
Ningbo Menovo Pharmaceutical Co., Ltd.'s (SHSE:603538) Price Is Right But Growth Is Lacking